{{Rsnum
|rsid=9594759
|Chromosome=13
|position=42458457
|Orientation=plus
|GMAF=0.4229
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 24.1 | 48.2 | 27.7
| HCB | 58.8 | 36.8 | 4.4
| JPT | 68.1 | 27.4 | 4.4
| YRI | 33.3 | 48.3 | 18.4
| ASW | 36.8 | 50.9 | 12.3
| CHB | 58.8 | 36.8 | 4.4
| CHD | 56.0 | 38.5 | 5.5
| GIH | 25.7 | 49.5 | 24.8
| LWK | 34.3 | 42.6 | 23.1
| MEX | 33.3 | 45.6 | 21.1
| MKK | 12.3 | 47.1 | 40.6
| TSI | 17.0 | 54.0 | 29.0
| HapMapRevision=28
}}rs9594759 increases susceptibility to Bone mineral density variations, lower for carriers of the T allele {{PMID|18445777}}

{{GWAS Summary
|SNP=rs9594759
|PubMedID=18445777
|Condition=Bone mineral density (spine)
|Gene=RANKL
|Risk Allele=T
|pValue=2.00E-021
|OR=0.17
|95CI=0.14-0.21) SD decreas
}}

{{PMID Auto GWAS
|PMID=19079262
|Trait=Bone mineral density (spine)
|Title=New sequence variants associated with bone mineral density
|RiskAllele=T
|Pval=2E-17
|OR=0.12
|ORtxt=[0.09-0.15] SD decrease
}}

{{omim
|desc=BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 9; BMND9
|id=612110
|rsnum=9594759
}}

{{PharmGKB
|RSID=rs9594759
|Name_s=
|Gene_s=NAA16
|Feature=
|Evidence=PubMed ID:19079262; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: New sequence variants associated with bone mineral density. (Initial Sample Size: 6,865 individuals; Replication Sample Size: 8,510 individuals); (Region: 13q14.11; Reported Gene(s): RANKL; Risk Allele: rs9594759-T); (p-value= 0.00000000000000002).This variant is associated with Bone mineral density (spine).
|Drugs=
|Drug Classes=
|Diseases=Bone Diseases; Bone Diseases, Metabolic
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740138
}}

{{PharmGKB
|RSID=rs9594759
|Name_s=
|Gene_s=NAA16
|Feature=
|Evidence=PubMed ID:18445777; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Multiple Genetic Loci for Bone Mineral Density and Fractures (Initial Sample Size: 5,861 individuals; Replication Sample Size: 7,925 individuals; Risk Allele: rs9594759-T). This variant is associated with Bone mineral density (spine).
|Drugs=
|Drug Classes=
|Diseases=Bone Diseases; Bone Diseases, Metabolic; Fractures, Bone
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356563
}}

{{PMID Auto
|PMID=22370887
|Title=Are bone mineral density loci associated with hip osteoporotic fractures? A validation study on previously reported genome-wide association loci in a Chinese population
|OA=1
}}

{{PMID|19181680|OA=1
}} Common variants in the region around Osterix are associated with bone mineral density and growth in childhood.

{{PMID|19629617|OA=1
}} Replication study of candidate genes/loci associated with osteoporosis based on genome-wide screening.

{{PMID|20072603|OA=1
}} Genome-wide association study identifies ALDH7A1 as a novel susceptibility gene for osteoporosis.

{{PMID|20205168}} Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men.

{{PMID Auto
|PMID=23072920
|Title=Genetic markers of bone and joint health and physical capability in older adults: the HALCyon programme
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9594759
|overall_frequency_n=46
|overall_frequency_d=124
|overall_frequency=0.370968
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=37
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}